Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan

Abstract Purpose Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. Me...

Полное описание

Библиографические подробности

Главные авторы:	Hiroki Irie, Rei Suzuki, Yoshinori Okubo, Hiroyuki Asama, Naoki Konno, Yuki Noguchi, Ko Watanabe, Goro Shibukawa, Hidemichi Imamura, Tadayuki Takagi, Mitsuru Sugimoto, Yuki Sato, Jun Nakamura, Tsunetaka Kato, Minami Hashimoto, Takumi Yanagita, Takuto Hikichi, Hiromasa Ohira
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2023-04-01
Серии:	BMC Cancer
Предметы:	Pancreatic ductal adenocarcinoma Chemotherapy Gemcitabine Nab-paclitaxel Interstitial lung disease
Online-ссылка:	https://doi.org/10.1186/s12885-023-10781-x
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!